🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Apollo Hospitals Enterprise Limited APOLLOHOSP NIFTY50NSEAIPHARMA

Healthcare · Medical Care Facilities · India
https://www.apollohospitals.com
Company Profile ↓
₹8,981.00
+22.36% 1Y
Mkt Cap₹1.29 L Cr
P/E66.51
P/B13.32
Div. Yield0.23%
52W High₹8,981.00
52W Low₹6,784.49
Book Value₹659.33
EPS (TTM)₹135.04

Company Overview

Apollo Hospitals Enterprise Limited, together with its subsidiaries, provides healthcare services in India. It operates through Healthcare Services, Retail Health & Diagnostics, Digital Health & Pharmacy Distribution, and Others segments. The company's healthcare facilities comprise primary, secondary, and tertiary care, as well as specialty facilities. It offers services in cardiac sciences, oncology, neurosciences, gastroenterology, orthopedics, urology, organ transplantation, pulmonology, obstetrics and gynecology, internal medicine, vascular surgery, pediatrics, cosmetology, emergency medicine, bariatric surgery, general surgery, colorectal surgery, dentistry, nephrology, dermatology, endocrinology, preventive medicine, interventional radiology, ophthalmology, and integrative medicine, as well as robotic surgery and genomics. The company also provides project consultancy, medical educational institutes, Medvarsity for e-learning, and research services, as well as acts as an agent for life, general, and health insurance. In addition, it operates hospitals, pharmacies, primary care clinics, and diagnostic centers; short stay facilities, boutique birthing centers, multi-specialty clinics, dental and dialysis facilities, and preventive care; day surgery, diabetes management, and cradle and fertility centers; and Apollo 24/7, a digital health mobile platform that provides teleconsultations, online pharmacy deliveries, home diagnostics, and insurance services. Further, the company engages in the business of bio-banking of tissues. It serves patients, corporate clients, and the government and public sectors. Apollo Hospitals Enterprise Limited was incorporated in 1979 and is based in Chennai, India.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 20.5%, reflecting efficient use of shareholder capital.

Healthy Capital Returns

Return on capital employed stands at 19.8%.

Consistent Profit Growth

Net profit has compounded at 33.3% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 15.3% CAGR over the past five years.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Mar 2026 Revenue of ₹25,228.50 Cr (+15.8% YoY); net profit ₹1,941.70 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +15.8%, earnings +34.3%.
  • 5-Year Trend Long-term compounding — revenue CAGR 15.3%, profit CAGR 33.3%.

Growth & Price Performance

Compounded Sales Growth

5 Years:15.33%
1 Year:15.76%

Compounded Profit Growth

5 Years:33.34%
1 Year:34.29%

Stock Price Performance

1 Year:+22.36%
6 Months:+23.72%
3 Months:+16.65%
1 Month:+7.04%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

AI Exposure AI Healthcare / Clinical AI & Diagnostics
Core Focus

Apollo Hospitals is deploying AI across clinical and operational workflows. Key initiatives: Apollo AI Health Platform for early disease detection (AI ECG, AI radiology), precision oncology AI via Apollo Proton Cancer Centre, predictive readmission models, and AI-powered pharmacy management (Apollo Pharmacy chain). Also partnered with Microsoft for clinical AI and 'Ask Apollo' AI health assistant.

Key Initiatives
  • Clinical AI & early-diagnosis tools Apollo's AI-powered cardiac risk score (AICVD) and clinical-decision-support tools screen patients for cardiovascular and other risks, scaling specialist expertise across its hospital network.
  • Apollo 24|7 digital-health AI The 24|7 platform uses AI for symptom triage, teleconsultation routing and personalised care pathways, monetising Apollo's clinical data across pharmacy and diagnostics.
  • AI in hospital operations Machine learning for bed management, demand forecasting and diagnostics throughput improves asset utilisation across primary, secondary and tertiary facilities.
Why Investors Should Care
  • Clinical data from a leading hospital network is a hard-to-replicate asset for healthcare AI.
  • AI lifts both clinical outcomes and asset utilisation — ROE ~21.5% with a ~33% five-year profit CAGR.
  • Digital-health (24|7) optionality layers a tech multiple onto a defensive healthcare base.
  • Premium valuation (P/E ~63) reflects growth and the digital pivot — execution must continue.
AI InvestmentPart of ₹10,000 Cr+ 5-year capex plan — AI health tech a stated priority. Investment in Apollo HealthCo (digital health + pharmacy AI platform). Tie-up with Google Cloud for genomics AI.
AI RevenueHealthcare revenue ~₹19,000 Cr (FY25). Digital/AI health contributing to higher ARPU — AI diagnosis packages priced at premium. Apollo 24|7 telehealth app (AI-triaged) has 50M+ users. AI-driven pharmacy cross-sell improving.
ROI (Now)EBITDA margin improving to 13-14%. AI radiology reducing radiologist turnaround from hours to minutes — enabling 2x throughput without proportional staffing cost. AI early-warning for sepsis/ICU reducing adverse events.
ROI (Expected)AI health is Apollo's long-term moat. Analysts see Apollo HealthCo (digital arm) as a separate value unlock. Preventive AI health packages (annual subscription model) could add ₹3,000-5,000 Cr revenue by FY28.

Curated from public filings and analyst commentary; figures are illustrative.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Strong return on equity of 20.5%.
  • Compounding revenue at 15.3% over 5 years.
  • Profit CAGR of 33.3% over 5 years.
  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Trading at a high P/E of 66.5.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
66.51
Industry PE
39.97
Forward P/E
41.90
PEG Ratio
-
Book Value
₹659.33
Price to Book
13.32
P/S
5.01
EV/EBITDA
35.31
Dividend Yield
0.23%

Growth (CAGR)

Revenue 5Y
15.33%
Profit 5Y
33.34%
Revenue (YoY)
15.76%
Earnings (YoY)
34.29%

Profitability & Returns

ROCE
19.79%
ROE
20.48%
ROA
8.75%
Profit Margin
7.70%
Op Margin
11.47%
Gross Margin
48.17%
EPS (Latest Qtr)
₹36.76
EPS (TTM)
₹135.04

Balance Sheet & Liquidity

Debt/Equity
0.90
Quick Ratio
0.98
Current Ratio
1.06
Debt
₹8,492.90 Cr
Total Assets
₹22,196.90 Cr
Current Assets
₹6,899.80 Cr
Working Capital
₹418.50 Cr

Ownership

Promoter Holding
28.39%
Chg in Prom Hold
0.37%
FII / Inst Holding
48.32%
Chg in FII Hold
-0.33%

Financial Snapshot

Enterprise Value
₹1.29 L Cr
Total Revenue (TTM)
₹25,228.50 Cr
EBITDA
₹3,986.60 Cr
Free Cash Flow
₹893.70 Cr
Operating Cash Flow
₹2,855.70 Cr
Shares Outstanding
₹14.38 Cr
Gross Margin
48.17%
Payout Ratio
14.81%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,981.00 66.51 ₹1.29 L Cr 0.23% 19.79% 20.48% 15.33% 33.34%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,948.80 40.77 ₹4.68 L Cr 0.83% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 7,315.50 75.61 ₹1.94 L Cr 0.44% 18.96% 15.32% 11.27% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,952.20 87.70 ₹1.68 L Cr 0.78% 9.05% 25.79% 13.27% 20.22%
5 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,440.10 22.07 ₹1.16 L Cr 0.90% 14.86% 11.27% 7.23% 11.45%
6 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,137.40 22.71 ₹1.14 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
7 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,494.30 21.42 ₹1.14 L Cr 0.72% 28.42% 23.76% 19.10% 131.46%
8 MAXHEALTH Max Healthcare Institute Limited NSEAIPHARMA 1,099.00 99.82 ₹1.07 L Cr 0.18% 12.57% 13.42% 22.37% 9.34%
9 MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA 2,562.00 55.36 ₹1.06 L Cr 0.08% 13.75% 11.74% 17.73% 14.28%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 4,302.00 Cr4,418.00 Cr4,847.00 Cr4,851.00 Cr4,944.00 Cr5,086.00 Cr-5,526.90 Cr5,592.20 Cr5,842.10 Cr6,304.00 Cr6,477.40 Cr6,605.50 Cr
Cost of Revenue -------2,900.70 Cr2,928.60 Cr3,047.60 Cr-3,382.40 Cr3,402.00 Cr
Gross Profit -------2,626.20 Cr2,663.60 Cr2,794.50 Cr-3,095.00 Cr3,203.50 Cr
Operating Expenses 3,814.00 Cr3,909.00 Cr4,219.00 Cr4,237.00 Cr4,303.00 Cr4,410.00 Cr-2,049.30 Cr2,104.90 Cr2,157.30 Cr5,362.00 Cr2,348.90 Cr2,416.90 Cr
Operating Income 329.00 Cr342.00 Cr465.00 Cr447.00 Cr450.00 Cr498.00 Cr-576.90 Cr558.70 Cr637.20 Cr723.00 Cr746.10 Cr786.60 Cr
EBITDA 488.00 Cr509.00 Cr628.00 Cr614.00 Cr640.00 Cr675.00 Cr-830.60 Cr841.30 Cr905.70 Cr941.00 Cr1,013.80 Cr1,065.00 Cr
Interest Expense 95.00 Cr106.00 Cr111.00 Cr113.00 Cr119.00 Cr116.00 Cr-109.80 Cr114.80 Cr108.30 Cr110.00 Cr112.60 Cr119.10 Cr
Pretax Income 254.00 Cr270.00 Cr379.00 Cr363.00 Cr368.00 Cr430.00 Cr-536.20 Cr515.50 Cr582.70 Cr675.00 Cr682.00 Cr721.50 Cr
Tax Provision 109.22 Cr97.20 Cr128.86 Cr108.90 Cr110.40 Cr116.10 Cr-156.80 Cr101.00 Cr141.70 Cr182.25 Cr165.70 Cr170.20 Cr
Net Income 146.00 Cr173.00 Cr249.00 Cr254.00 Cr258.00 Cr316.00 Cr-372.30 Cr389.60 Cr432.80 Cr494.00 Cr502.30 Cr529.30 Cr
Diluted EPS 10.0511.5916.2017.0617.6521.23-25.8921.1030.1033.1934.9436.76

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 5,129.00 Cr6,150.00 Cr7,256.00 Cr8,243.00 Cr9,617.00 Cr11,247.00 Cr10,560.00 Cr-16,444.80 Cr18,862.30 Cr21,794.00 Cr25,228.50 Cr
Cost of Revenue --------8,574.30 Cr9,805.50 Cr11,310.00 Cr13,075.60 Cr
Gross Profit --------7,870.50 Cr9,056.80 Cr10,484.00 Cr12,152.90 Cr
Operating Expenses 4,392.00 Cr5,465.00 Cr6,522.00 Cr7,442.00 Cr8,548.00 Cr9,656.00 Cr9,420.00 Cr-6,421.30 Cr7,349.50 Cr8,219.70 Cr9,259.70 Cr
Operating Income 525.00 Cr420.00 Cr420.00 Cr442.00 Cr674.00 Cr971.00 Cr567.00 Cr-1,449.20 Cr1,707.30 Cr2,264.30 Cr2,893.20 Cr
EBITDA 737.00 Cr684.00 Cr734.00 Cr801.00 Cr1,070.00 Cr1,591.00 Cr1,140.00 Cr-2,072.80 Cr2,477.60 Cr3,255.10 Cr3,986.60 Cr
Interest Expense 118.00 Cr180.00 Cr257.00 Cr295.00 Cr327.00 Cr533.00 Cr449.00 Cr-313.70 Cr410.10 Cr458.50 Cr449.60 Cr
Pretax Income 455.00 Cr332.00 Cr222.00 Cr171.00 Cr373.00 Cr660.00 Cr221.00 Cr-1,143.70 Cr1,380.50 Cr2,039.10 Cr2,660.90 Cr
Tax Provision 131.95 Cr96.28 Cr91.02 Cr111.15 Cr175.31 Cr224.40 Cr83.98 Cr-256.20 Cr445.50 Cr534.00 Cr658.20 Cr
Net Income 335.00 Cr235.00 Cr131.00 Cr60.00 Cr200.00 Cr432.00 Cr137.00 Cr-819.10 Cr898.60 Cr1,445.90 Cr1,941.70 Cr
Diluted EPS 24.4316.9915.888.4416.9632.7010.46-56.9762.50100.56135.04

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 6,459.00 Cr7,360.00 Cr8,103.00 Cr8,596.00 Cr9,166.00 Cr11,289.00 Cr11,392.00 Cr-14,427.80 Cr16,753.10 Cr20,657.40 Cr22,196.90 Cr
Current Assets --------4,337.00 Cr5,279.70 Cr7,028.90 Cr6,899.80 Cr
Cash & Equivalents --------433.40 Cr505.50 Cr578.10 Cr811.30 Cr
Inventory --------390.10 Cr459.80 Cr480.80 Cr542.40 Cr
Receivables --------2,234.20 Cr2,514.90 Cr3,016.10 Cr3,484.90 Cr
Total Liabilities --------7,896.50 Cr9,432.60 Cr12,004.50 Cr12,222.40 Cr
Current Liabilities --------3,324.90 Cr4,664.50 Cr4,578.90 Cr6,481.30 Cr
Long Term Debt --------1,937.60 Cr2,235.60 Cr1,971.90 Cr2,430.10 Cr
Total Debt 1,992.00 Cr2,834.00 Cr3,125.00 Cr3,427.00 Cr3,673.00 Cr3,596.00 Cr4,160.00 Cr-4,332.40 Cr5,332.60 Cr5,419.20 Cr8,492.90 Cr
Total Equity 3,172.00 Cr3,332.00 Cr3,314.00 Cr3,252.00 Cr3,334.00 Cr3,340.00 Cr4,603.00 Cr-6,197.40 Cr6,935.40 Cr8,212.30 Cr9,480.10 Cr
Shares Outstanding --------14.38 Cr14.38 Cr14.38 Cr14.38 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow 470.00 Cr597.00 Cr623.00 Cr537.00 Cr905.00 Cr1,293.00 Cr1,265.00 Cr-1,376.90 Cr1,920.20 Cr2,136.40 Cr2,855.70 Cr
Investing Cash Flow -759.00 Cr-888.00 Cr-1,152.00 Cr-405.00 Cr-711.00 Cr-289.00 Cr-880.00 Cr--870.60 Cr-1,537.20 Cr-3,383.00 Cr-2,148.20 Cr
Financing Cash Flow 392.00 Cr330.00 Cr477.00 Cr-108.00 Cr-215.00 Cr-910.00 Cr-340.00 Cr--633.00 Cr-311.10 Cr1,319.20 Cr-477.60 Cr
Capital Expenditure -866.00 Cr-990.00 Cr-669.00 Cr-621.00 Cr-672.00 Cr-511.00 Cr-281.00 Cr--1,128.50 Cr-1,136.80 Cr-1,712.70 Cr-1,962.00 Cr
Free Cash Flow -396.00 Cr-393.00 Cr-46.00 Cr-84.00 Cr233.00 Cr782.00 Cr984.00 Cr-248.40 Cr783.40 Cr423.70 Cr893.70 Cr
Net Change in Cash 103.00 Cr39.00 Cr-52.00 Cr24.00 Cr-20.00 Cr94.00 Cr44.00 Cr--126.70 Cr71.90 Cr72.60 Cr229.90 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % --------47.9%48.0%48.1%48.2%
Operating Margin % 10.2%6.8%5.8%5.4%7.0%8.6%5.4%-8.8%9.1%10.4%11.5%
Net Margin % 6.5%3.8%1.8%0.7%2.1%3.8%1.3%-5.0%4.8%6.6%7.7%
ROE % 10.6%7.1%4.0%1.8%6.0%12.9%3.0%-13.2%13.0%17.6%20.5%
ROCE % --------13.1%14.1%14.1%18.4%

Shareholding Pattern

Insiders
28.39%
Institutions
48.32%
Public Float
67.48%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for APOLLOHOSP

Google News ue, 14 Jul 2026

Share Market Today: Nifty 50, Bank Nifty | July 14, 2026 - Liquide Blog

<a href="https://news.google.com/rss/articles/CBMi0AFBVV95cUxQYWVQVFYtVDd0ZUowZnEyelJaRWhfNGtZeGJtbXpoT3V5LTZCczJ2UlNmYXlfRnZJSW5JdWlEcTJrOHA1MkxfVjk2QzhWMzJiaGU2cFltMmEtOVdfN2hhdE9ETUxVaHRKV1RYUjVzU2wteTRYdTQ0MWJHcUdtZEZTSzBYYmZCbUFzUWJZaV…

Google News hu, 21 May 2026

Apollo Hospitals shares hit 52-week high on strong Q4 results; should you buy, sell or hold? - TradingView

<a href="https://news.google.com/rss/articles/CBMi5wFBVV95cUxNS3ZJLVBaRDJZRl9WV1NKaUNjWWFOUHVEaHV1bGRldWlFM3luVGtTdlVISk9ndVZfU2ZYYXFZclhaVkZHRlJiNmd6R0NlWHpzRUYxSVhFVE5jYjN2VE1xR0k4RTBlckFRYkdnWlZuLTFSWUxHQ1VpSEctSy1welIzTnNqN3VpelVMV2pzSz…

Google News Sat, 13 Dec 2025

Could The Market Be Wrong About Apollo Hospitals Enterprise Limited (NSE:APOLLOHOSP) Given Its Attractive Financial Prospects? - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi7gFBVV95cUxNSTIycTBnLXlIVmo4ZUdidW5qQm9DbEhDel95MFJTWTRDYk4tVDRIUTFaZHNrYTh4NmZ2OVo0U2FzT0VpX2EyNTlTRWl4blBEdW9zY3dPbEZoVzdkNTJMNmJzWndHRWVlRl81dndzeExrcEVnQU9qNk14M2dvUy1XbE9OZ2hfVzgtcHY0M1…

Google News Fri, 10 Jul 2026

APOLLOHOSP Outlook for the Week (July 13, 2026 – July 17, 2026) - Equitypandit

<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTE9IVDBTamZZWldiUF9feDNQTF91NE51X2lIVXh1M1JHUkk5U1NJSEFQSFZGWkRLQ2FMblhHbEh1ZFNhYjh1YTZkUUIxSVlDX2VqZUJWU29wU0JKbk8xSFd2LTM4V0p5RGZuc3kza193?oc=5" target="_blank">APOLLOHOSP Outlook …

Google News Wed, 20 May 2026

Apollo Hospitals Enterprise Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026 - marketscreener.com

<a href="https://news.google.com/rss/articles/CBMi5gFBVV95cUxPSUpnUlQ0VE5RdTZkaV9QeDNRbmU3dTMzU0QtT0hXTnlfNUJmaUY5aFloNlJFZl9NbnZ4cEZnaW1tcXFadzdtZTdWUk9kZnJ0UURwRTVrNENYRUNOYU9fdjViYkdSQTZPbVhSWmQ2SXRrWF9mYnNDSnlHTWk2aXY4SFBFVUc5dXdIWmdqdH…

Google News Wed, 28 Jan 2026

Apollo Hospitals Enterprise's (NSE:APOLLOHOSP) investors will be pleased with their strong 154% return over the last five years - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi8gFBVV95cUxNSmtIR09aR05Wel9sV0R1aEd3X3U2QTRpblc3VWUtN3B6MlAteXJiX1F4Ym9CSUJZMkFIdkppYzdpalJJV3psRU9EbDk4SWZGb3owbXFjMlNYVmN2Um8xUzI3U3lGNzlIVUJkLXZfQUhHNi1NRDZZb1RLQl92TDA1XzVVN2dQRDdGeEtFRj…

APOLLOHOSP — Frequently Asked Questions

What is the current share price of Apollo Hospitals Enterprise Limited (APOLLOHOSP)?

As of 2026-07-15 09:52 IST, Apollo Hospitals Enterprise Limited (APOLLOHOSP) trades at ₹8,981.00 on NSE. Its 52-week range is ₹6,784.49 to ₹8,981.00.

What is the market capitalisation of APOLLOHOSP?

Apollo Hospitals Enterprise Limited (APOLLOHOSP) has a market capitalisation of ₹1.29 L Cr on NSE.

What is the P/E ratio of APOLLOHOSP?

APOLLOHOSP trades at a trailing price-to-earnings (P/E) ratio of 66.51. The industry average P/E is 39.97. Its price-to-book (P/B) ratio is 13.32.

Does APOLLOHOSP pay a dividend?

Apollo Hospitals Enterprise Limited (APOLLOHOSP) currently offers a dividend yield of 0.23%.

What is the return on equity (ROE) of APOLLOHOSP?

APOLLOHOSP has a return on equity (ROE) of 20.48%. Its return on capital employed (ROCE) is 19.79%.

Is APOLLOHOSP a good stock to buy?

This page provides a data-driven analysis of Apollo Hospitals Enterprise Limited (APOLLOHOSP), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space